The Rise of CBD in Combat Sport
From Brazilian jiu jitsu to MMA and boxing – combat sports athletes are embracing CBD oil in a big way. Dozens of fighters around...
It may come as no surprise to those in the know about CBD, that the private monopolisation of this non-toxic, powerful substance has begun.
Online CBD seller Leafly, reported last week that British drug manufacturer GW Pharma and its American subsidiary, Greenwich BioSciences, are “quietly” trying to move proprietary bills into two states over in America. If the bills are passed, it will give GW a temporary monopoly on legal CBD sales in South Dakota and Nebraska.
The bills are centred around GW’s controversial Epiodolex drug, a CBD-based drug that’s been developed to treat pediatric epilepsy and is currently in Phase III clinical trials. If the drug is FDA approved and GW’s bills get passed, they will be the only company allowed to legally sell a CBD product in both states.
With vast amounts of studies available regarding the benefits of these non-toxic products, the government should be looking at opening up access opportunities to CBD, not closing them down by giving legality to one sole trader.
“Greenwich Biosciences/GW is not creating a monopoly. Rather, we are blazing a trail for any other CBD prescription medications that may follow since these regulations would not be specific to GW. In fact, it is likely new companies may be encouraged to enter the field of cannabinoid research, leading to a greater number of cannabinoid treatment options for patients, not fewer.”
Now, this all seems very honourable but the problem with this statement is that GW are lobbying for a bill that bans anyone else selling a CBD product unless it is FDA approved, and unsurprisingly, Epiodolex is the only product that is anyway near this approval.
So where does this leave us; and more importantly where does it leave patients currently relying on CBD products to help them improve their general health and wellbeing?
Do you think this is the start of the monopolisation of medicine by commercial pharmaceuticals? Does money talk more than a patient’s pain? Let us know your thoughts!
Subscribe to the CBD Ultra mailing list for new product information, offers and news delivered directly to your inbox.